• ACTIVExtend: BMD response increases long term with abaloparatide followed by alendronate

    One year ago - By Healio

    Lorraine A. Fitzpatrick
    CHICAGO - Postmenopausal women with osteoporosis saw increased bone mineral density and reduced fracture risks over 43 months with alendronate follow-up to both abaloparatide therapy and placebo, but improvements were substantially greater with the abaloparatide-alendronate regimen, according to results of a prespecified responder analysis of ACTIVExtend data reported here.
    “This study showed that the number of people who responded by having an increase in bone mineral density with the abaloparatide group vs. placebo was much higher. When the study was
    Read more ...